-
1
-
-
39049120759
-
Medical treatment of advanced testicular cancer
-
Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ,. Medical treatment of advanced testicular cancer. JAMA. 2008; 299: 672-684.
-
(2008)
JAMA
, vol.299
, pp. 672-684
-
-
Feldman, D.R.1
Bosl, G.J.2
Sheinfeld, J.3
Motzer, R.J.4
-
3
-
-
3142577828
-
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group
-
Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004; 22: 108-114.
-
(2004)
J Clin Oncol
, vol.22
, pp. 108-114
-
-
Kollmannsberger, C.1
Beyer, J.2
Liersch, R.3
-
4
-
-
33749235727
-
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor
-
discussion 38-39
-
De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol. 2006; 50: 1032-1038; discussion 38-39.
-
(2006)
Eur Urol
, vol.50
, pp. 1032-1038
-
-
De Giorgi, U.1
Rosti, G.2
Aieta, M.3
-
5
-
-
11144355665
-
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study
-
Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004; 15: 493-497.
-
(2004)
Ann Oncol
, vol.15
, pp. 493-497
-
-
Pectasides, D.1
Pectasides, M.2
Farmakis, D.3
-
6
-
-
0025141586
-
Phase II study of daily oral etoposide in refractory germ cell tumors
-
Miller JC, Einhorn LH,. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990; 17 (1 suppl 2): 36-39.
-
(1990)
Semin Oncol
, vol.17
, Issue.1 SUPPL. 2
, pp. 36-39
-
-
Miller, J.C.1
Einhorn, L.H.2
-
7
-
-
0035154256
-
Clinical trial designs for cytostatic agents: Are new approaches needed?
-
Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC,. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001; 19: 265-272.
-
(2001)
J Clin Oncol
, vol.19
, pp. 265-272
-
-
Korn, E.L.1
Arbuck, S.G.2
Pluda, J.M.3
Simon, R.4
Kaplan, R.S.5
Christian, M.C.6
-
8
-
-
0026731918
-
Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression
-
Motzer RJ, Nanus DM, O'Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 1992; 52: 5775-5779.
-
(1992)
Cancer Res
, vol.52
, pp. 5775-5779
-
-
Motzer, R.J.1
Nanus, D.M.2
O'Moore, P.3
-
9
-
-
0028984044
-
All-trans retinoic acid for treating germ cell tumors. in vitro activity and results of a phase II trial
-
Moasser MM, Motzer RJ, Khoo KS, et al. all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 1995; 76: 680-686.
-
(1995)
Cancer
, vol.76
, pp. 680-686
-
-
Moasser, M.M.1
Motzer, R.J.2
Khoo, K.S.3
-
10
-
-
0028860716
-
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors
-
Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ,. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 1995; 13: 163-165.
-
(1995)
Invest New Drugs
, vol.13
, pp. 163-165
-
-
Puc, H.S.1
Bajorin, D.F.2
Bosl, G.J.3
Amsterdam, A.4
Motzer, R.J.5
-
11
-
-
0033894907
-
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors
-
Vuky J, McCaffrey J, Ginsberg M, et al. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2000; 18: 265-267.
-
(2000)
Invest New Drugs
, vol.18
, pp. 265-267
-
-
Vuky, J.1
McCaffrey, J.2
Ginsberg, M.3
-
12
-
-
10744223010
-
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
-
Kondagunta GV, Bacik J, Schwartz L, et al. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2004; 22: 177-179.
-
(2004)
Invest New Drugs
, vol.22
, pp. 177-179
-
-
Kondagunta, G.V.1
Bacik, J.2
Schwartz, L.3
-
13
-
-
34547702867
-
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
-
Feldman DR, Kondagunta GV, Ginsberg MS, et al. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2007; 25: 487-490.
-
(2007)
Invest New Drugs
, vol.25
, pp. 487-490
-
-
Feldman, D.R.1
Kondagunta, G.V.2
Ginsberg, M.S.3
-
14
-
-
77956621875
-
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
-
Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010; 28: 523-528.
-
(2010)
Invest New Drugs
, vol.28
, pp. 523-528
-
-
Feldman, D.R.1
Turkula, S.2
Ginsberg, M.S.3
-
15
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
Simon R,. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
16
-
-
0034018538
-
Results of treatment after relapse from high-dose chemotherapy in germ cell tumors
-
Porcu P, Bhatia S, Sharma M, Einhorn LH,. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol. 2000; 18: 1181-1186.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1181-1186
-
-
Porcu, P.1
Bhatia, S.2
Sharma, M.3
Einhorn, L.H.4
|